NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …
Tag Archives: Lycera
January, 2017
June, 2015
-
9 June
Celgene Enters $105 Million Cancer Immunotherapy Collaboration with Lycera
Celgene has entered into a new cancer immunotherapy deal that could provide privately-held Lycera Corp. up to $105 million-plus. Lycera announced the formation of an exclusive global collaboration with Celgene to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases. Lycera said that Celgene will license its portfolio of RORgamma …